Recombinant proteins

Global Pegfilgrastim Biosimilars Market Report 2020-2030

Retrieved on: 
Friday, February 5, 2021

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Pegfilgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Pegfilgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi.
  • The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them.
  • Global Pegfilgrastim Biosimilars Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

BioHarvest Sciences Inc. Signs an Exclusive Agreement with Cukierman & Co. Life Sciences to Explore Pharmaceutical Partnerships for the Use of VINIA(R) as an Adjuvant Therapy in Type 2 Diabetes Treatments

Retrieved on: 
Thursday, February 4, 2021

The primary purpose of the agreement is for Cukierman to assist BioHarvest in forming strategic and commercial partnerships with relevant pharmaceutical companies.

Key Points: 
  • The primary purpose of the agreement is for Cukierman to assist BioHarvest in forming strategic and commercial partnerships with relevant pharmaceutical companies.
  • BioHarvest has also completed a clinical trial administering VINIA to type 2 diabetes patients being treated with oral antidiabetic medications (no insulin).
  • Accordingly, the Company has decided to engage Cukierman to assist the Company in engaging with relevant players in the pharmaceutical industry.
  • Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent protected BioFarming technology.

Global Pegfilgrastim Biosimilars Market Report 2020-2030: Major Players are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 4, 2021

The "Pegfilgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pegfilgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi.
  • The global pegfilgrastim biosimilar market is expected to decline from $534.43 million in 2019 to $453.11 million in 2020 at a compound annual growth rate (CAGR) of -15.22%.
  • The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them.

Global Biosimilar Growth Hormones Market Report 2020-2030: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome & Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 4, 2021

The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The biosimilar growth hormone market consists of sales of Somatropin or human growth hormone (HGH) and related services by entities (organizations, sole traders and partnerships) that manufacture growth hormones.
  • The biosimilar growth hormone market covered in this report is segmented by route of administration into intravenous; subcutaneous; intramuscular; oral.
  • The growing number of children suffering from growth hormone deficiency is driving the growth of the global biosimilar growth hormone market.

Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

Retrieved on: 
Wednesday, February 3, 2021

No shares or other securities are being offered to the public by means of this press release.

Key Points: 
  • No shares or other securities are being offered to the public by means of this press release.
  • Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
  • In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.
  • Real world Bleeding Rates over 7 Years of Antihemophilic Factor (recombinant) in Patients with Hemophilia A and Target Joints: AHEAD International
    3 EAHAD 2021.

Lilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries

Retrieved on: 
Thursday, January 28, 2021

Additionally, Life for a Child announced a new strategic partnership with Beyond Type 1, a global diabetes nonprofit focused on changing what it means to live with chronic illness.

Key Points: 
  • Additionally, Life for a Child announced a new strategic partnership with Beyond Type 1, a global diabetes nonprofit focused on changing what it means to live with chronic illness.
  • Type 1 diabetes management support includes access to mealtime and basal insulins, reusable pens, blood glucose monitoring, A1C testing and diabetes education.
  • "Lilly and Life for a Child have been collaborating for years to develop solutions, and we are excited to strengthen this critical work with Beyond Type 1."
  • The expanded partnership will enable Life for a Child to reach children and young people in more than 60 countries, including India, Pakistan, Ethiopia, Tanzania, and Bolivia.

Global Insulin Delivery System Market (2020 to 2025) - by Product Type and End-user - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 21, 2021

What is the market size and forecast of the Global Insulin Delivery System Market?

Key Points: 
  • What is the market size and forecast of the Global Insulin Delivery System Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Insulin Delivery System Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Insulin Delivery System Market?
  • What are the modes and strategic moves considered suitable for entering the Global Insulin Delivery System Market?

Insulet’s Omnipod DASH® System Now Available in Canada

Retrieved on: 
Monday, January 18, 2021

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced the launch of the Omnipod DASH Insulin Management System (Omnipod DASH System) in Canada.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced the launch of the Omnipod DASH Insulin Management System (Omnipod DASH System) in Canada.
  • The Omnipod System has been a vital part of my diabetes management since 2013 and I am excited that the Omnipod DASH is coming to Canada, said Esther Funk, a Registered Nurse and Certified Pump Trainer living with Type 1 diabetes.
  • Insulet plans to launch the Omnipod DASH System throughout Canada on a province-by-province basis throughout 2021 to coincide with reimbursement by provincial health programs.
  • About the Omnipod DASH System:
    The Omnipod DASH Insulin Management System is the first and only tubeless device that can provide three days of non-stop insulin delivery.

Global Pegfilgrastim Biosimilars Market Report 2020-2030: Market Growth is Mainly Due to an Increased Prevalence of Cancer and Increased Adoption of Biosimilars

Retrieved on: 
Thursday, January 14, 2021

The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019.

Key Points: 
  • The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019.
  • The growth is mainly due to an increased prevalence of cancer and increased adoption of the biosimilars.
  • The pegfilgrastim biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies and mail order/ online pharmacies.
  • North America was the largest region in the global pegfilgrastim biosimilars market, accounting for 51.1% of the total in 2019.

Global Pegfilgrastim Biosimilars Market Opportunities and Strategies to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 13, 2021

The "Pegfilgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pegfilgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
  • The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019.
  • The hospital pharmacies was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 89.8% of the total market in 2019.
  • North America was the largest region in the global pegfilgrastim biosimilars market, accounting for 51.1% of the total in 2019.